Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 453

1.

Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.

Gulati S, Desai J, Palackdharry SM, Morris JC, Zhu Z, Jandarov R, Riaz MK, Takiar V, Mierzwa M, Gutkind JS, Molinolo A, Desai PB, Sadraei NH, Wise-Draper TM.

Cancer. 2019 Oct 18. doi: 10.1002/cncr.32539. [Epub ahead of print]

PMID:
31626727
2.

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance.

Zainal NS, Lee BKB, Wong ZW, Chin IS, Yee PS, Gan CP, Mun KS, Rahman ZAA, Gutkind JS, Patel V, Cheong SC.

Cancer Biol Med. 2019 May;16(2):264-275. doi: 10.20892/j.issn.2095-3941.2018.0257.

3.

Endothelial RhoA GTPase is essential for in vitro endothelial functions but dispensable for physiological in vivo angiogenesis.

Zahra FT, Sajib MS, Ichiyama Y, Akwii RG, Tullar PE, Cobos C, Minchew SA, Doçi CL, Zheng Y, Kubota Y, Gutkind JS, Mikelis CM.

Sci Rep. 2019 Aug 12;9(1):11666. doi: 10.1038/s41598-019-48053-z.

4.

Beyond Synthetic Lethality: Charting the Landscape of Pairwise Gene Expression States Associated with Survival in Cancer.

Magen A, Das Sahu A, Lee JS, Sharmin M, Lugo A, Gutkind JS, Schäffer AA, Ruppin E, Hannenhalli S.

Cell Rep. 2019 Jul 23;28(4):938-948.e6. doi: 10.1016/j.celrep.2019.06.067.

5.

Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm.

Raimondi F, Inoue A, Kadji FMN, Shuai N, Gonzalez JC, Singh G, de la Vega AA, Sotillo R, Fischer B, Aoki J, Gutkind JS, Russell RB.

Oncogene. 2019 Sep;38(38):6491-6506. doi: 10.1038/s41388-019-0895-2. Epub 2019 Jul 23.

6.

Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.

Wu X, Yeerna H, Goto Y, Ando T, Wu VH, Zhang X, Wang Z, Amornphimoltham P, Murphy AN, Tamayo P, Chen Q, Lippman SM, Gutkind JS.

Cancer Res. 2019 Sep 1;79(17):4360-4370. doi: 10.1158/0008-5472.CAN-18-3525. Epub 2019 Jul 10.

PMID:
31292160
7.

Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Wu V, Yeerna H, Nohata N, Chiou J, Harismendy O, Raimondi F, Inoue A, Russell RB, Tamayo P, Gutkind JS.

J Biol Chem. 2019 Jul 19;294(29):11062-11086. doi: 10.1074/jbc.REV119.005601. Epub 2019 Jun 5. Review.

8.

Illuminating G-Protein-Coupling Selectivity of GPCRs.

Inoue A, Raimondi F, Kadji FMN, Singh G, Kishi T, Uwamizu A, Ono Y, Shinjo Y, Ishida S, Arang N, Kawakami K, Gutkind JS, Aoki J, Russell RB.

Cell. 2019 Jun 13;177(7):1933-1947.e25. doi: 10.1016/j.cell.2019.04.044. Epub 2019 May 31.

9.

PRECOG: PREdicting COupling probabilities of G-protein coupled receptors.

Singh G, Inoue A, Gutkind JS, Russell RB, Raimondi F.

Nucleic Acids Res. 2019 Jul 2;47(W1):W395-W401. doi: 10.1093/nar/gkz392.

10.

4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer.

Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, Ando M, Wahba A, Amornphimoltham P, Wu X, Gilardi M, Allevato M, Wu V, Steffen DJ, Tofilon P, Sonenberg N, Califano J, Chen Q, Lippman SM, Gutkind JS.

Cancer Res. 2019 Apr 1;79(7):1438-1450. doi: 10.1158/0008-5472.CAN-18-1220. Epub 2019 Mar 20.

PMID:
30894372
11.

Direct targeting of Gαq and Gα11 oncoproteins in cancer cells.

Annala S, Feng X, Shridhar N, Eryilmaz F, Patt J, Yang J, Pfeil EM, Cervantes-Villagrana RD, Inoue A, Häberlein F, Slodczyk T, Reher R, Kehraus S, Monteleone S, Schrage R, Heycke N, Rick U, Engel S, Pfeifer A, Kolb P, König G, Bünemann M, Tüting T, Vázquez-Prado J, Gutkind JS, Gaffal E, Kostenis E.

Sci Signal. 2019 Mar 19;12(573). pii: eaau5948. doi: 10.1126/scisignal.aau5948.

PMID:
30890659
12.

Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.

Sahu AD, S Lee J, Wang Z, Zhang G, Iglesias-Bartolome R, Tian T, Wei Z, Miao B, Nair NU, Ponomarova O, Friedman AA, Amzallag A, Moll T, Kasumova G, Greninger P, Egan RK, Damon LJ, Frederick DT, Jerby-Arnon L, Wagner A, Cheng K, Park SG, Robinson W, Gardner K, Boland G, Hannenhalli S, Herlyn M, Benes C, Flaherty K, Luo J, Gutkind JS, Ruppin E.

Mol Syst Biol. 2019 Mar 11;15(3):e8323. doi: 10.15252/msb.20188323.

13.

Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.

Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB.

Clin Cancer Res. 2019 Jul 15;25(14):4211-4223. doi: 10.1158/1078-0432.CCR-18-0871. Epub 2019 Feb 27. Review.

PMID:
30814108
14.

Structure of the C-terminal guanine nucleotide exchange factor module of Trio in an autoinhibited conformation reveals its oncogenic potential.

Bandekar SJ, Arang N, Tully ES, Tang BA, Barton BL, Li S, Gutkind JS, Tesmer JJG.

Sci Signal. 2019 Feb 19;12(569). pii: eaav2449. doi: 10.1126/scisignal.aav2449.

15.

A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.

Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS.

Cancer Cell. 2019 Mar 18;35(3):457-472.e5. doi: 10.1016/j.ccell.2019.01.009. Epub 2019 Feb 14.

PMID:
30773340
16.

SOX2 Epidermal Overexpression Promotes Cutaneous Wound Healing via Activation of EGFR/MEK/ERK Signaling Mediated by EGFR Ligands.

Uchiyama A, Nayak S, Graf R, Cross M, Hasneen K, Gutkind JS, Brooks SR, Morasso MI.

J Invest Dermatol. 2019 Aug;139(8):1809-1820.e8. doi: 10.1016/j.jid.2019.02.004. Epub 2019 Feb 14.

PMID:
30772301
17.

cAMP-dependent activation of the Rac guanine exchange factor P-REX1 by type I protein kinase A (PKA) regulatory subunits.

Adame-García SR, Cervantes-Villagrana RD, Orduña-Castillo LB, Del Rio JC, Gutkind JS, Reyes-Cruz G, Taylor SS, Vázquez-Prado J.

J Biol Chem. 2019 Feb 15;294(7):2232-2246. doi: 10.1074/jbc.RA118.006691. Epub 2018 Dec 10.

18.

Gβγ signaling to the chemotactic effector P-REX1 and mammalian cell migration is directly regulated by Gαq and Gα13 proteins.

Cervantes-Villagrana RD, Adame-García SR, García-Jiménez I, Color-Aparicio VM, Beltrán-Navarro YM, König GM, Kostenis E, Reyes-Cruz G, Gutkind JS, Vázquez-Prado J.

J Biol Chem. 2019 Jan 11;294(2):531-546. doi: 10.1074/jbc.RA118.006254. Epub 2018 Nov 16.

PMID:
30446620
19.

Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.

Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS.

Clin Cancer Res. 2019 Feb 15;25(4):1156-1164. doi: 10.1158/1078-0432.CCR-18-2024. Epub 2018 Nov 12.

PMID:
30420444
20.

Development of a yeast-based system to identify new hBRAFV600E functional interactors.

Lubrano S, Comelli L, Piccirilli C, Marranci A, Dapporto F, Tantillo E, Gemignani F, Gutkind JS, Salvetti A, Chiorino G, Cozza G, Chiariello M, Galli A, Poliseno L, Cervelli T.

Oncogene. 2019 Feb;38(8):1355-1366. doi: 10.1038/s41388-018-0496-5. Epub 2018 Sep 20.

PMID:
30237439
21.

Correction to: mTOR co-targeting strategies for head and neck cancer therapy.

Wang Z, Valera JC, Zhao X, Chen Q, Gutkind JS.

Cancer Metastasis Rev. 2019 Jun;38(1-2):327. doi: 10.1007/s10555-018-9765-6.

PMID:
30187213
22.

GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling.

Ideno N, Yamaguchi H, Ghosh B, Gupta S, Okumura T, Steffen DJ, Fisher CG, Wood LD, Singhi AD, Nakamura M, Gutkind JS, Maitra A.

Gastroenterology. 2018 Nov;155(5):1593-1607.e12. doi: 10.1053/j.gastro.2018.08.006. Epub 2018 Aug 22.

PMID:
30142336
23.

Transcriptional signature primes human oral mucosa for rapid wound healing.

Iglesias-Bartolome R, Uchiyama A, Molinolo AA, Abusleme L, Brooks SR, Callejas-Valera JL, Edwards D, Doci C, Asselin-Labat ML, Onaitis MW, Moutsopoulos NM, Gutkind JS, Morasso MI.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaap8798. doi: 10.1126/scitranslmed.aap8798.

24.

The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras.

Oliva JL, Zarich N, Martínez N, Jorge R, Castrillo A, Azañedo M, García-Vargas S, Gutiérrez-Eisman S, Juarranz A, Boscá L, Gutkind JS, Rojas JM.

J Biol Chem. 2018 Jul 20;293(29):11651. doi: 10.1074/jbc.W118.004644. No abstract available.

25.

Arrestins as rheostats of GPCR signalling.

Gutkind JS, Kostenis E.

Nat Rev Mol Cell Biol. 2018 Oct;19(10):615-616. doi: 10.1038/s41580-018-0041-y. No abstract available.

PMID:
30026541
26.

Assembly and activation of the Hippo signalome by FAT1 tumor suppressor.

Martin D, Degese MS, Vitale-Cross L, Iglesias-Bartolome R, Valera JLC, Wang Z, Feng X, Yeerna H, Vadmal V, Moroishi T, Thorne RF, Zaida M, Siegele B, Cheong SC, Molinolo AA, Samuels Y, Tamayo P, Guan KL, Lippman SM, Lyons JG, Gutkind JS.

Nat Commun. 2018 Jul 9;9(1):2372. doi: 10.1038/s41467-018-04590-1.

27.

Head and Neck Cancer in the New Era of Precision Medicine.

Nör JE, Gutkind JS.

J Dent Res. 2018 Jun;97(6):601-602. doi: 10.1177/0022034518772278. No abstract available.

PMID:
29771196
28.

GENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems.

Lee BKB, Gan CP, Chang JK, Tan JL, Fadlullah MZ, Abdul Rahman ZA, Prime SS, Gutkind JS, Liew CS, Khang TF, Tan AC, Cheong SC.

J Dent Res. 2018 Jul;97(8):909-916. doi: 10.1177/0022034518759038. Epub 2018 Mar 7.

PMID:
29512401
29.

The homozygous CX3CR1-M280 mutation impairs human monocyte survival.

Collar AL, Swamydas M, O'Hayre M, Sajib MS, Hoffman KW, Singh SP, Mourad A, Johnson MD, Ferre EM, Farber JM, Lim JK, Mikelis CM, Gutkind JS, Lionakis MS.

JCI Insight. 2018 Feb 8;3(3). pii: 95417. doi: 10.1172/jci.insight.95417. eCollection 2018 Feb 8.

30.

Expression of an active Gαs mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance.

Zhao X, Deng P, Iglesias-Bartolome R, Amornphimoltham P, Steffen DJ, Jin Y, Molinolo AA, de Castro LF, Ovejero D, Yuan Q, Chen Q, Han X, Bai D, Taylor SS, Yang Y, Collins MT, Gutkind JS.

Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E428-E437. doi: 10.1073/pnas.1713710115. Epub 2017 Dec 27.

31.

The NOTCH4-HEY1 Pathway Induces Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.

Fukusumi T, Guo TW, Sakai A, Ando M, Ren S, Haft S, Liu C, Amornphimoltham P, Gutkind JS, Califano JA.

Clin Cancer Res. 2018 Feb 1;24(3):619-633. doi: 10.1158/1078-0432.CCR-17-1366. Epub 2017 Nov 16.

32.

The Next Frontier: Head and Neck Cancer Immunoprevention.

Gutkind JS, Bui JD.

Cancer Prev Res (Phila). 2017 Dec;10(12):681-683. doi: 10.1158/1940-6207.CAPR-17-0331. Epub 2017 Nov 14.

33.

Genetic variants affecting equivalent protein family positions reflect human diversity.

Raimondi F, Betts MJ, Lu Q, Inoue A, Gutkind JS, Russell RB.

Sci Rep. 2017 Oct 6;7(1):12771. doi: 10.1038/s41598-017-12971-7.

34.

A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers.

Guo T, Sakai A, Afsari B, Considine M, Danilova L, Favorov AV, Yegnasubramanian S, Kelley DZ, Flam E, Ha PK, Khan Z, Wheelan SJ, Gutkind JS, Fertig EJ, Gaykalova DA, Califano J.

Cancer Res. 2017 Oct 1;77(19):5248-5258. doi: 10.1158/0008-5472.CAN-16-3106. Epub 2017 Jul 21.

35.

Genetic evidence that β-arrestins are dispensable for the initiation of β2-adrenergic receptor signaling to ERK.

O'Hayre M, Eichel K, Avino S, Zhao X, Steffen DJ, Feng X, Kawakami K, Aoki J, Messer K, Sunahara R, Inoue A, von Zastrow M, Gutkind JS.

Sci Signal. 2017 Jun 20;10(484). pii: eaal3395. doi: 10.1126/scisignal.aal3395.

36.

E1a is an exogenous in vivo tumour suppressor.

Cimas FJ, Callejas-Valera JL, García-Olmo DC, Hernández-Losa J, Melgar-Rojas P, Ruiz-Hidalgo MJ, Pascual-Serra R, Ortega-Muelas M, Roche O, Marcos P, Garcia-Gil E, Fernandez-Aroca DM, Ramón Y Cajal S, Gutkind JS, Sanchez-Prieto R.

Cancer Lett. 2017 Jul 28;399:74-81. doi: 10.1016/j.canlet.2017.04.010. Epub 2017 Apr 15.

PMID:
28416454
37.

Epidermal loss of Gαq confers a migratory and differentiation defect in keratinocytes.

Doçi CL, Mikelis CM, Callejas-Valera JL, Hansen KK, Molinolo AA, Inoue A, Offermanns S, Gutkind JS.

PLoS One. 2017 Mar 16;12(3):e0173692. doi: 10.1371/journal.pone.0173692. eCollection 2017.

38.

Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.

Carter H, Marty R, Hofree M, Gross AM, Jensen J, Fisch KM, Wu X, DeBoever C, Van Nostrand EL, Song Y, Wheeler E, Kreisberg JF, Lippman SM, Yeo GW, Gutkind JS, Ideker T.

Cancer Discov. 2017 Apr;7(4):410-423. doi: 10.1158/2159-8290.CD-16-1045. Epub 2017 Feb 10.

39.

Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC.

Gaykalova DA, Zizkova V, Guo T, Tiscareno I, Wei Y, Vatapalli R, Hennessey PT, Ahn J, Danilova L, Khan Z, Bishop JA, Gutkind JS, Koch WM, Westra WH, Fertig EJ, Ochs MF, Califano JA.

Oncotarget. 2017 Feb 28;8(9):15349-15363. doi: 10.18632/oncotarget.14856.

40.

LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.

Deng WW, Mao L, Yu GT, Bu LL, Ma SR, Liu B, Gutkind JS, Kulkarni AB, Zhang WF, Sun ZJ.

Oncoimmunology. 2016 Oct 7;5(11):e1239005. doi: 10.1080/2162402X.2016.1239005. eCollection 2016.

41.

Using Heterologous COS-7 Cells to Identify Semaphorin-Signaling Components.

Sakurai A, Doçi CL, Gutkind JS.

Methods Mol Biol. 2017;1493:163-170.

PMID:
27787849
42.

Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer.

Nohata N, Goto Y, Gutkind JS.

J Hum Genet. 2017 Jan;62(1):87-96. doi: 10.1038/jhg.2016.124. Epub 2016 Oct 13. Review.

PMID:
27734836
43.

mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model.

Callejas-Valera JL, Iglesias-Bartolome R, Amornphimoltham P, Palacios-Garcia J, Martin D, Califano JA, Molinolo AA, Gutkind JS.

Carcinogenesis. 2016 Oct;37(10):1014-25. doi: 10.1093/carcin/bgw086. Epub 2016 Aug 18.

44.

WNT Stimulation Dissociates a Frizzled 4 Inactive-State Complex with Gα12/13.

Arthofer E, Hot B, Petersen J, Strakova K, Jäger S, Grundmann M, Kostenis E, Gutkind JS, Schulte G.

Mol Pharmacol. 2016 Oct;90(4):447-59. doi: 10.1124/mol.116.104919. Epub 2016 Jul 25.

45.

Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection.

Nohata N, Abba MC, Gutkind JS.

Oral Oncol. 2016 Aug;59:58-66. doi: 10.1016/j.oraloncology.2016.05.014. Review.

46.

Liver kinase B1 regulates hepatocellular tight junction distribution and function in vivo.

Porat-Shliom N, Tietgens AJ, Van Itallie CM, Vitale-Cross L, Jarnik M, Harding OJ, Anderson JM, Gutkind JS, Weigert R, Arias IM.

Hepatology. 2016 Oct;64(4):1317-29. doi: 10.1002/hep.28724. Epub 2016 Jul 28.

47.

Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer.

Andradas C, Blasco-Benito S, Castillo-Lluva S, Dillenburg-Pilla P, Diez-Alarcia R, Juanes-García A, García-Taboada E, Hernando-Llorente R, Soriano J, Hamann S, Wenners A, Alkatout I, Klapper W, Rocken C, Bauer M, Arnold N, Quintanilla M, Megías D, Vicente-Manzanares M, Urigüen L, Gutkind JS, Guzmán M, Pérez-Gómez E, Sánchez C.

Oncotarget. 2016 Jul 26;7(30):47565-47575. doi: 10.18632/oncotarget.10206.

48.

PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells.

Alonso N, Diaz Nebreda A, Monczor F, Gutkind JS, Davio C, Fernandez N, Shayo C.

Biochim Biophys Acta. 2016 Sep;1860(9):1998-2007. doi: 10.1016/j.bbagen.2016.06.016. Epub 2016 Jun 15.

PMID:
27316323
49.

Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, Martin D, Gutkind JS, Hedberg ML, Grandis JR, Argiris A.

Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.

PMID:
27232378
50.

NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.

Zhao ZL, Zhang L, Huang CF, Ma SR, Bu LL, Liu JF, Yu GT, Liu B, Gutkind JS, Kulkarni AB, Zhang WF, Sun ZJ.

Sci Rep. 2016 Apr 25;6:24704. doi: 10.1038/srep24704.

Supplemental Content

Loading ...
Support Center